327 results about "Head injury sequelae" patented technology

Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of an ointment, cream, gel, lotion, spray, foam, paste, patch, suspension or dispersion. In the preferred embodiment, the formulation is a gel. The LV may contain a penetration enhancer, most preferably one with membrane disruptive properties. The formulation may be applied to or impregnated into a gauze, wrap, bandage, cotton-tipped stick, adhesive bandage strip, or other support wrap or medical bandage or wound cover. For example, the compositions may be are incorporated onto or into disposables such as hemorrhoid wipes, sponge, mouth guards, dental trays; needles or catheters; adult diapers; gloves, socks or wrist bands, for ease of application. The composition is applied topically to a site at or adjacent to a painful region. The composition is reapplied as necessary. Pain relief is typically obtained within minutes and lasts for periods of variable duration ranging from minutes to several hours and even, in some cases, days. The composition is variably effective to treat visceral, somatic and neuropathic pain both acute and chronic as well as muscle pain and stiffness and joint pain and stiffness.

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention/reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

Methods and pharmaceutical compositions of matter are disclosed and claimed relating to cardioprotective effect mediated by delta ( delta ) opioid receptor agonists or more specifically delta-1 ( delta 1)-opioid receptor agonists. Further, methods drawn to reducing ischemic damage to organs and tissues having delta ( delta ) opioid receptor agonists or more specifically delta-1 ( delta 1)-opioid receptors are disclosed and claimed. Specifically, methods and pharmaceutical compositions of matter are taught as a means of providing cardioprotective treatment through the administration of delta ( delta ) opioid receptor agonists or more specifically delta-1 ( delta 1)-opioid receptor agonists, such as TAN67(-). Said methods and pharmaceutical compositions are envisioned as a means of reducing myocardial infarction arising from the onset and sequelae of myocardial ischemia.

One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

A Chinese medicine for treating neuralgia, vascular headache, cerebral ischemia and cerebral apoplexy sequelae is prepared from 41 Chinese-medicinal materials including ginseng, astragalus root, Chinese angelica root, white peony root, etc.

The invention relates to a Chinese patient medicament for treating cardiovascular and cerebrovascular diseases and a preparation method thereof. The Chinese patient medicament is prepared from the following raw materials by weight: 0.3 gram of cornu saigae tatariace powder, 12 grams of tabasheer, 15 grams of grassleaf sweelflag rhizome, 15 grams of sea-ear shell, 10 grams of nacre, 15 grams of raw dragon bone and oyster shell, 12 grams of thinleaf milkwort root-bark, 12 grams of bamboo shavings, 20 grams of salivia chinensis, 15 grams of tall gastrodia tuber, 20 grams of gambir plant, 20 grams of common selfheal fruit-spike, 10 grams of radix geutianae, 20 grams of dendrobium, 30 grams of liquor white paeony root, 30 grams of vinegar white paeony root, 30 grams of raw white paeony root, 12 grams of radix curcumae, 15 grams of vinegar Chinese thorowax root, 15 grams of liquor rhubarb, 0.1 gram of musk, 12 grams of turtle shell, 15 grams of stiff silkworm, 20 grams of sanguisuga, 30 grams of earthworm, 25 grams of kudzuvine root, 10 grams of scorpion, 15 grams of desertliving cistanche, 6 grams of liquorice root, 100 grams of astragalus, 15 grams of szechwon tangshen root, 20 grams of heterophylly falsestarwort root, 15 grams of liquor Chinese angelica, 12 grams of szechuan lovage rhizome, 12 grams of safflower and the like. The Chinese patient medicament has the advantages of preventing the evolution period and sequelae of the cardiovascular and cerebrovascular diseases from generating and overcoming the defect that other treatment methods make patients generate medicinal tolerance to various medicaments.

Provided herein are bioactive agents comprising a compound that inhibits the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR) and that is linked to a macromolecule that interacts with a cell that expresses CFTR. The bioactive agents described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, secretory diarrhea.

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

A pure traditional Chinese medicine preparation for treating cardiovascular diseases is characterized in that the pure traditional Chinese medicine preparation is prepared by traditional Chinese medicine raw materials with the following parts by weight: 5-10 parts of safflower, 10-20 parts of motherwort herb, 4-8 parts of danshen root, 4-8 parts of Szechuan lovage rhizome, 2-4 parts of medicinal cyathula root, 3-6 parts of peach seed, 2-4 parts of trogopterus dung, 2-4 parts of common burreed rhizome, 2-4 parts of zedoary, 2-4 parts of turmeric, 1-2 parts of dragon blood, 3-6 parts of clematis root, 2-4 parts of gentiana macrophylla, 2-4 parts of heracleum hemsleyanum michaux, 2-4 parts of radix stephaniae tetrandrael, 2-4 parts of sea-ear shell, 2-4 parts of oyster shell, 2-4 parts of puncturevine caltrop fruit, 3-6 parts of uncaria, 1-2 parts of stiff silkworm, 0.2-0.4 part of scorpion, 4-8 parts of rhubarb, 2-4 parts of ephedra herb, 2-4 parts of pepperweed seed, 2-4 parts of bitter apricot seed, 2-4 parts of sessile stemona root, 4-8 parts of unibract fritillary bulb, 2-4 parts of snakegourd fruit, 2-4 parts of arisaema cum bile, 2-4 parts of pinellia tuber, 2-4 parts of nutgrass galingale rhizome, 2-4 parts of rhizoma corydalis, 2-4 parts of Chinese eaglewood, 2-4 parts of cassia seed, 2-4 parts of common selfheal fruit-spike, 1-2 parts of cicada slough, 3-6 parts of honeysuckle flower, 2-4 parts of chrysanthemum, 3-6 parts of baical skullcap root, 2-4 parts of golden thread, 2-4 parts of tree peony bark, 4-8 parts of red paeony root, 4-8 parts of tuber fleeceflower root and 4-8 parts of membranous milk vetch root. The pure traditional Chinese medicine preparation is used for treating various cardiovascular diseases, the sequelae and the complications thereof.

The present invention relates to compositions and methods for antimicrobial dental materials in the restoration of the sequelae of oral infections including replacement of oral tissues lost to disease and prevention of additional infections.

The invention relates to medicinal liquor for treating bone disease, which comprises the following substances by weight: 50 parts of Panax japonicum, 50 parts of tuber santsigu, 50 parts of ground beetle, 50 parts of safflower, 15 parts of Paris polyphylla, 15 parts of rhizoma drynariae, 18 parts of pseudo-ginseng, 30 parts of Sanguis Draconis, 50 parts of radix clematidis, 20 parts of myrrh, 50 parts of gardenia jasminoides, 12 parts of dried orange peel, 30 parts of cortex eucommiae, 30 parts of chaff flower root, 30 parts of pawpaw, 30 parts of buck grass, 30 parts of cassia twig, 50 partsof fiveleaf akebia, 24 parts of coralbean bark and 24 parts of common dodder. The present invention also relates to a method for preparing the medicinal liquor. The medicinal liquor provided by the invention can be used for treating rheumatic numbness of limbs, rheumatic arthritis, cervical spondylosis, periarthritis humeroscapularis, ischialgia caused by lumbar muscle strain, hyperosteogeny, hernia of intervertebral disc, spondylosis and ischemic necrosis of femoral head, traumatic injury, bone fracture, soft tissue contusion sequelae and the like.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

The invention provides a collateral dredging and inflammation diminishing analgesic ointment, and relates to medicines for treating herpes zoster, scapulohumeral periarthritis and traumatic injuries. The ointment comprises the following medicinal materials: Chinese angelica, red peony root, raw rehmmania root, radix scrophulariae, scutellaria baicalensis, coptidis rhizoma, cortex phellodendri, rheum officinale, lonicera japonica, earthworm, ligusticum wallichii, gecko, ground beetle, leech, safflower, camphor, angelica root, pangolin, frankincense, myrrh, dragon's blood, catechu, fructus forsythiae, nidus vespae, liquorice and borneol. The ointment is prepared by the following steps: soaking raw materials except borneol in 2.0-2.4kg of sesame oil for 5-7 days; decocting until the mixture is black with slow fire; removing dregs, adding 1.0-1.2kg of yellow lead, and keeping on decocting until the dropping mixture forms a bead shape; removing from the fire and cooling; adding borneol into the mixture, uniformly stirring, and spreading into patches. The collateral dredging and inflammation diminishing analgesic ointment has the advantages that the treatment effect is good, the cure rate is high, one patch of the ointment is used for 3 days and can be used for relieving pains in 8-12 hours, pains can be cured in 3 days generally, and certain individual syndromes need two patches and can be cured in 6 days; sequelae are not left; clinical testing on 229 cases indicates that the effective rate of the ointment is 100 percent; the ointment is prepared by using a pure traditional Chinese medicinal formula, and has small toxic and side effects.

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.